NCT05775406View on ClinicalTrials.gov

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions
Myeloid MalignanciesAcute Lymphocytic LeukemiaLymphomasAdvanced Solid Tumors
Interventions
DRUG

KT-253

KT-253 will be administered intravenously per the defined protocol frequency and dose level.

Trial Locations (11)

10065

Memorial Sloan Kettering Cancer Center, New York

10467

Montefiore Medical Center, The Bronx

22031

Inova Schar Cancer Institute, Fairfax

48202

Henry Ford Health System, Detroit

73104

OU Health Stephenson Cancer Center, Oklahoma City

75230

Mary Crowley Cancer Research, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

77030

MD Anderson Cancer Center, Houston

85258

HonorHealth Research Institute, Scottsdale

95817

University of California, Davis Comprehensive Cancer Center, Sacramento

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Kymera Therapeutics, Inc.

INDUSTRY

NCT05775406 - Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | Biotech Hunter | Biotech Hunter